Protecting the Blind in Clinical Trials

This white paper discusses the critical importance of maintaining the integrity of blinded studies in clinical trials. It outlines the risks associated with accidental unblinding, including both full and partial unblinding incidents, and the potential consequences such as loss of patient data. The document details how advanced Randomization and Trial Supply Management (RTSM) systems, specifically Prancer RTSM™, incorporate safeguards to mitigate these risks. It explains scenarios that can lead to unblinding, such as improper report aggregation, screen sharing during virtual meetings, and inventory management issues. The paper emphasizes the need for clear identification of blinded and unblinded report versions and the importance of maintaining consistent lot identifiers. Additionally, it addresses challenges related to shipment blinding and the management of kit types in adaptive study designs. The strategies presented aim to minimize risks while ensuring that clinical trials can operate effectively without compromising data integrity.